Clinical Trial Update: Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis 2 (ZOLARMAB2) [Phase 4]

View source ↗

Summary

Phase 4 trial examining zoledronate after denosumab in postmenopausal osteoporosis; the study (ZOLARMAB2) is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Denosumab (Prolia) (denosumab)
• Zoledronate (Reclast) (Zoledronic acid)

Snippet

Sponsor: Aarhus University Hospital | Conditions: Osteoporosis, Postmenopausal | Phase 4 | Status: ACTIVE_NOT_RECRUITING